AGENUS Aktie

 >AGENUS Aktienkurs 
3.41 EUR    (Tradegate)
Ask: 3.45 EUR / 956 Stück
Bid: 3.37 EUR / 978 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
>AGENUS Performance
1 Woche: -5,1%
1 Monat: -13,3%
3 Monate: +9,0%
6 Monate: +38,5%
1 Jahr: +48,8%
laufendes Jahr: -7,7%
>AGENUS Aktie
Name:  AGENUS INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00847G7051 / A1JLKZ
Symbol/ Ticker:  AJ81 (Frankfurt) / AGEN (NASDAQ)
Kürzel:  FRA:AJ81, AJ81.F, AJ81:GR, NASDAQ:AGEN
Index:  -
Webseite:  http://www.agenusbio.com
Marktkapitalisierung:  686.37 Mio. EUR
Umsatz:  82.09 Mio. EUR
EBITDA:  -88.3 Mio. EUR
Gewinn je Aktie:  -0.969 EUR
Schulden:  32.73 Mio. EUR
Liquide Mittel:  67.34 Mio. EUR
Umsatz-/ Gewinnwachstum:  71.50% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  6.43 / - / -
Gewinnm./ Eigenkapitalr.:  -173.74% / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Suchwörter:  AGENUS
Letzte Datenerhebung:  20.10.20
>AGENUS Eigentümer
Aktien: 183.44 Mio. St.
f.h. Aktien: 115.2 Mio. St.
Insider Eigner: 19.71%
Instit. Eigner: 41.54%
Leerverk. Aktien: 14.12%
>AGENUS Peer Group

 
20.10.20 - 16:36
Agenus to Report Third Quarter Earnings (GlobeNewswire EN)
 
Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am...
14.10.20 - 23:03
Agenus to Present on Seven Novel Programs at SITC 2020 (GlobeNewswire EN)
 
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers an...
13.10.20 - 15:02
AGENUS INC: 8-K Report (SEC Filing)
 
8-K...
13.10.20 - 14:33
Susan Hirsch Joins Agenus′ Board of Directors (GlobeNewswire EN)
 
LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers an...
30.09.20 - 09:37
Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.09.20 - 23:52
Agenus First Data From MK-4830: Another Reason To Buy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.09.20 - 19:34
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab (Zacks)
 
Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer....
18.09.20 - 16:16
Looking Into Agenus′s Return On Capital Employed (Benzinga)
 
Agenus (NASDAQ: AGEN) reported Q2 sales of $26.95 million. Earnings fell to a loss of $26.43 million, resulting in a 17.0% decrease from last quarter. Agenus collected $15.13 million in revenue during Q1, but reported earnings showed a $31.85 million...
18.09.20 - 14:52
Agenus initiates rolling BLA submission of Balstilimab (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.09.20 - 14:33
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer (GlobeNewswire EN)
 
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers a...
18.09.20 - 13:37
Agenus PD-1 inhibitor shows positive effect in cervical cancer (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.09.20 - 13:16
Agenus balstilimab shows clinical activity in both PD-L1 positive and negative tumors (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.09.20 - 09:03
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO (GlobeNewswire EN)
 
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers a...
17.09.20 - 23:06
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With (GlobeNewswire EN)
 
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers a...
17.09.20 - 19:42
Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline (GlobeNewswire EN)
 
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers a...
11.09.20 - 16:48
Thinking about buying stock in Avinger, Vascular Biogenics, Intra-Cellular Therapies, Agenus, or Co-Diagnostics? (PR Newswire)
 
NEW YORK , Sept. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, VBLT, ITCI, AGEN, and CODX....
11.09.20 - 16:40
Return On Capital Employed Overview: Agenus (Benzinga)
 
During Q2, Agenus (NASDAQ: AGEN) brought in sales totaling $26.95 million. However, earnings decreased 17.0%, resulting in a loss of $26.43 million. In Q1, Agenus brought in $15.13 million in sales but lost $31.85 million in earnings. read more...
10.09.20 - 20:31
Why Agenus Is Soaring 23.6% Today (Fool)
 
Investor optimism is increasing ahead of an oral presentation at ESMO 2020....
10.09.20 - 17:16
Agenus, Achieve Life Sciences leads gainers, Satsuma Pharmaceuticals, Precipio among losers (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.08.20 - 14:32
AGENUS INC: 8-K Report (SEC Filing)
 
8-K...
>Zitat des Tages: Der Gütige läßt die Art, wie er einen geliebten Menschen behandelt, auch den Ungeliebten zuteil werden. - Mengtse
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ Boersentreff.de - Die Märkte im Blick!